Bayer Seeking Levitra Label Without Alpha Blocker Contraindication
This article was originally published in The Pink Sheet Daily
Executive Summary
Second quarter sales for Levitra were lower than expected, hampered by a slow erectile dysfunction market, the company says. Bayer remains optimistic about long-term Levitra sales growth despite competition from Pfizer and Lilly.
You may also be interested in...
Schering/GSK Levitra Labeling Drops Alpha Blocker Contraindication
Alpha blocker/PDE-5 inhibitor contraindication in vardenafil labeling is downgraded to precaution; the language is identical to a recent revision for Lilly’s Cialis. References on concomitant use with alpha blockers are now on par with Cialis and Pfizer’s Viagra.
Schering/GSK Levitra Labeling Drops Alpha Blocker Contraindication
Alpha blocker/PDE-5 inhibitor contraindication in vardenafil labeling is downgraded to precaution; the language is identical to a recent revision for Lilly’s Cialis. References on concomitant use with alpha blockers are now on par with Cialis and Pfizer’s Viagra.
Cialis Sheds Alpha Blocker Contraindication
Lilly/Icos’ erectile dysfunction agent revises labeling to include a new subsection on alpha blockers within the Precautions section, but no contraindication. Schering Plough/GlaxoSmithKline’s Levitra is now the only PDE5 inhibitor with the contraindication.